Article -> Article Details
Title | Agoraphobia Market Size, Demand, Cost Structures, and Future Forecasts to 2023 |
---|---|
Category | Fitness Health --> Health Insurance |
Meta Keywords | Agoraphobia Market |
Owner | vinit |
Description | |
Market Overview Desensitization triggered by exposure therapy results in
familiarization which makes the condition better. The therapist assists the
patient to comprehend thought patterns, false attitudes, and false beliefs,
which raises concern, with an objective to transform the thought process and to
shape the thought patterns more helpful and realistic. Anti-anxiety drugs
called benzodiazepines find wide application in relieving acute fretfulness
since they are known to form habits. Alternative medicines and dietary
supplements have been tested and found to be beneficial. Market Research Future
has conducted an exhaustive study on the global Agoraphobia
treatment market and concluded that Agoraphobia diagnosis and
treatment market is likely to attain $800 mn by the conclusion of 2023. The
market is anticipated to develop at a CAGR of 4.3 % over the forecast period
2017-2023. Agoraphobia is prevalent in around 1.7% of adults with women
having a high propensity to be affected by the ailment. Agoraphobia diagnosis
and treatment market is significantly fueled by aspects like expanding
incidence of stress, sedentary lifestyles, genetic disposition, growing
screening and awareness, substance abuse, lack of affection in relations,
worsening health standards in the modern lifestyles, etc. The factors that
restrict the market growth include low focus and penetration of mental health
in society, inclination to hide mental ailments, unwillingness to treatment and
therapy, social stigma related to psychotherapy, etc. Cognitive behavioral cure
is the key psychotherapy for agoraphobia. Cognitive behavioral therapy mostly
involves teaching skill to endure anxiety in a better way, challenging the
worries, and projecting the most realistic and probable outcomes of the place
or situation. Exposure therapy is another efficient way of dealing with the
symptoms of Agoraphobia. The therapy focuses on increasing the exposure to
situations which causes a panic attack and to tolerate and cope with the
consequence that follows. Agoraphobia refers to the anxiety related to situations
or places that causes panic stricken behavior accompanied by a feeling of being
helpless or trapped. The situation might be real or imaginary such as traveling
a public conveyance, being present in an enclosed space or being surrounded by
a crowd. Symptoms and signs of a panic attack in agoraphobia include troubled
breathing, increased heart rate, dizziness, chest pain, feeling of loss of
control, excessive sweating, and fear of dying. Agoraphobia is predominantly
triggered by a blend of environmental and genetic factors. Other symptoms
consist of posttraumatic depression, stress, and separation anxiety.
Agoraphobia patients suffer from a surged risk of substance use disorder and
depression. Market Segmentation The global agoraphobia market is segmented based on therapy,
end users, and drug treatment. Based on therapy, the market is segmented into
exposure therapy, cognitive behavioral therapy (CBT), psychotherapy, and
others. Based on the end users, the market is segmented into academics,
clinics, hospitals, and others. Based on drug treatment, the market is
segmented into norepinephrine reuptake inhibitors, selective serotonin reuptake
inhibitors, anti-anxiety medications, tricyclic antidepressants, and others. Regional Analysis The US market represents a major share of global Agoraphobia
treatment sector owing to the outstanding reimbursement set-up, surged outlay
on healthcare, and favorable insurance programs. The faster market approval of
novel devices and technologies in the US is also a significant driver of the
global market for agoraphobia diagnosis and treatment. Europe market holds
the second largest share owing to the affluence of the population and their
rising awareness about mental health. The Middle East Africa market is
dominated by the Gulf nations specifically UAE and Saudi Arabia. Key Players Global Agoraphobia market is largely dominated by renowned
players such as Eli Lilly Co., Bristol-Myers Squibb, AstraZeneca,
GlaxoSmithKline plc, Sandoz Inc., Pfizer inc, Mylan Pharmaceuticals Inc., and
Apotex Corp. |